Treatment of osteoporosis with regard of evidence-based medicine;Evidenzbasierte therapie der osteoporose

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 17, 2003, Pages 931-934

  Minne, Helmut W ^a,b   Pfeifer, M ^a  

^a Inst Klin Osteologie Gustav Pommer   (Germany)

^b Klin Der Fürstenhog   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FRACTURE; HORMONAL THERAPY; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK FACTOR; SUPPLEMENTATION;

EVIDENCE-BASED MEDICINE; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS;

EID: 0038415714     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38851     Document Type: Review

References (20)

1. Begerow B, Pfeifer M, Pospeschill M et al. Time since vertebral fracture: an important variable concerning quality of life in patients with postmenopausal osteoporosis. Osteoporos Int 1999; 10: 26-33
2. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541
3. Chesnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109: 267-276
4. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998; 280: 2077-2082
5. Delmas PD, Bjarnason LH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-1647
6. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-645
7. Felsenberg D, Silman AJ, Lunt M et al. for the European Prospective Osteoporosis Study (EPOS) Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17: 716-724
8. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999; 282: 1344-1352
9. Lieberman UA, Weiss SR, Bröll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443
10. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-340
11. Minne HW, Pfeifer M, Begerow B, Pollähne M. Osteoporose. Orthopäde 2002; 31: 681-699
12. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441
13. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610
14. Pfeifer M, Wittenberg R, Würtz R, Minne HW. Schenkelhalsfrakturen in Deutschland. Dt Ärztebl 2001; 98: A1751-A1757
15. Pfeifer M, Lehmann R, Minne HW. Die Therapie der Osteoporose aus dem Blickwinkel einer auf Evidenz basierenden Medizin. Med Klin 2001; 96: 270-280
16. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113-1118
17. Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporos Int 2002; 13: 187-194
18. Pollähne W, Bröll H, Burckhardt P, Delling G, Minne HW. Therapie primärer und sekundärer Osteoporosen. 1. Auflage Stuttgart New York; Thieme, 1999: 21-28
19. Reginster JY, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91
20. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-299